DEVAFIDUGENE CIVAPARVOVEC
Mucopolysaccharidosis II
Sangamo Therapeuticsgene_therapyActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the Mucopolysaccharidosis II cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gc1111 Takeda | Phase 4 | A |
PABINAFUSP ALFA JCR Pharmaceuticals Co., Ltd. | Phase 3 | BBB |
Idursulfase Beta GC Biopharma Corp | Phase 3 | BBB |
Rgx-121 REGENXBIO Inc. | Phase 3 | BB |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Takeda | Phase 4 | BB |
View all 32 →
Same molecule, other indications
DEVAFIDUGENE CIVAPARVOVEC is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →